ArticleCancer immunology, immunotherapy : CII2019

MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.

Selma Ugurel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.